Over the course of 40 years, the management of HIV has drastically changed. A wide variety of medications and data shape the current treatment of HIV. However, pockets of people with HIV still remain with barriers to successful outcomes, such as those with low-level viraemia and the highly treatment experienced. Transitions of care become critical for specific populations to ensure access and treatment are available. Comorbidities such as dyslipidaemia also impact outcomes. Looking forward, injectable medications will become more available to all people with HIV as injectable programmes are integrated into usual care and more injectable options are available.
Review
This is a narrative review of the growing evidence of low-level viraemia in people living with HIV to determine risk factors and antiretroviral therapy management strategies and to discuss the implications of low-level viraemia on the development of future virological failure.
Review
This narrative review provides an overview of the clinician approach to care, including diagnostics, approaches to regimen creation, relevant resources, and a broad array of
both currently available and upcoming antiretrovirals that may be used in regimens for heavily treatment-experienced patients.
Review
This article aims to provide a narrative updated review on the clinical evaluation and management of dyslipidaemia in people with HIV.
Commentary
This article discusses three transitions of care that may lead to suboptimal outcomes if people with HIV are not adequately engaged: adolescent to adult, prison to society and the postpartum period.
Commentary
In this commentary, the authors describe experiences to date with acquiring, storing, handling, administering and billing for long-acting cabotegravir and rilpivirine through four scenarios, each of which have presented their own unique obstacles and learning curves.
